We describe simple, clinically useful double-antibody fluoroimmunoassays for amikacin, gentamicin, tobramycin, theophylline, and phenytoin. The fluorescent tracers were prepared by conjugation to fluorescein isothiocyanate; the antisera were raised in rabbits. A simple filter fluorometer and disposable culture tubes are used. with a filter fluorometer. A nonlinear standard curve is generated from which an unknown in a patient's sample can be quantified.
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The therapeutically effective concentration for theophylline in serum is between 10 and 20 mg/L (1), with seizures resulting from toxicity reported for the range 25-70 mg/L (2) . The importance of monitoring the phenytoin in serum has also been well established (3) (4) (5) . Control of concentrations of aminoglycosides in serum is critical, because the therapeutic range is narrow. High concentrations of an aminoglycoside can result in nephrotoxicity and damage to the eighth cranial nerve (6, 7) . Clearly, the need for therapeutic monitoring of such drugs has been well established.
Cm-rent methods for doing so include RIA, "high-performance" liquid chromatography, EIA (8, 9) , substrate-labeled fluoroimmunoassay (10, 11) , fluorescence polarization immunoassay (12) (13) (14) (15) (16) (17) (18) (19) , and fluoroimmunoassay (20) (21) (22) with a filter fluorometer. A nonlinear standard curve is generated from which an unknown in a patient's sample can be quantified. Precision.
Materials and Methods

Materials
Intra-assay precision
was assessed from the mean of 20 concurrent assays per sample. Inter-assay precision was determined from the mean of the average of duplicates for 20 separate runs. Samples were prepared with the appropriate drug dissolved in normal human serum. Table 1 summarizes the results.
Sensitivity.
The limit of detection of the dose-response curve (defined as equivalent to 2 SD) was determined from 20 replicates of a zero-dose standard.
The results for each drug, in mg/L (and pmolltube), are as follows: phenytoin, 0.30 (1.2) ; theophylline, 0.20 (1.1); gentamicin, 0.50 (0.9); amikacin, 0.20 (3.4); and tobramycin, 0.60 (1.3).
Analytical recovery. Recoveries (Table 2) for all assays were quantitative, as determined by supplementing drugfree human serum with the appropriate drug and comparing the assayed value with the expected value.
Specificity.
We evaluated the cross reactivity of each antibody for compounds that could interfere with the various assays. To do this, we added increasing concentrations of a suspected cross reactant to a standard that fell at the midpoint of the therapeutic range. The results (Tables 3 and   4 ) are reported as the amount of cross reactant required to Interfering substances. Bilir#{252}bin, hemoglobin, and triglycerides were evaluated for possible interference in the assay.
The results (Table 6 ) indicate no notable interference by bilirubin, hemoglobin, or triglycerides.
Correlation with Commercially Available Assays
The FIA for phenytoin was compared with two commercially ayailable radioimmunoassays (RJ.A) and a homogeneous EIA. The same samples were run in duplicate in each assay. The lines of best fit were calculated by the least squares method. The FIA for phenytoin was compared with two RIA kits and one EIA. The results are summarized in Figure 2 .
The FLA for theophylline was compared with one RIA kit and EIA (Figure 3 ).
________________
The FIA for gentamicin was compared with one RIA kit and one EIA (Figure 4) .
The amikacin FIA was compared with two commercially available RIA kits ( Figure 5 ).
The tobramycin FLA was compared with one RIA kit and EIA ( Figure 6 ). We find this heterogeneous double-antibody approach to be suitable not only for the drugs described, but also for many other drugs of interest.
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